The evolving role of perioperative systemic therapy in bladder cancer
Related Experiment Video
Updated: Nov 1, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Saad O Atiq1, Jonathan F Anker1, Eric J Miller1
1Division of Hematology/Oncology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Abstract:
The treatment landscape for muscle-invasive bladder cancer has recently been transformed by two key phase 3 studies of perioperative enfortumab vedotin plus pembrolizumab. These trials have demonstrated significant improvements in event-free survival and overall survival compared with the previous standards of care, marking a new era in the management of patients with muscle-invasive bladder cancer that is no longer defined by cisplatin eligibility. The focus is now shifting toward the identification of additional novel therapeutic targets for further improved outcomes as well as response-guided treatment pathways seeking to optimize both cancer control and survivorship.
Related Concept Videos
Urinary Tract Calculi VI: Surgical Management
Kidney Transplant II: Surgical Procedure
Treatment Resistant Cancers
Treatment Resistent Cancers
Urinary Tract Calculi III: Medical Management